10-K: Propanc Biopharma Reports Soaring Losses Amid R&D Focus

Propanc Biopharma, a biopharmaceutical company, reported a significant increase in net loss to $58.9 million for fiscal year 2025, driven by substantial stock-based compensation, while advancing its lead cancer drug candidate, PRP, towards Phase Ib clinical trials.

Summary

• Propanc Biopharma is a biopharmaceutical company focused on developing novel proenzyme therapy (PRP) to prevent recurrence and metastasis from solid tumors, particularly pancreatic, ovarian, and colorectal cancers.
• The company reported a net loss of $58,923,300 for the fiscal year ended June 30, 2025, a substantial increase from $1,820,528 in the prior year.
• Administration expenses surged to $57,027,850 in fiscal 2025, primarily due to $37,800,000 in stock-based compensation to officers and an employee, and $18,169,000 for stock-based consulting and legal services.
• Research and development expenses decreased slightly to $223,721 in fiscal 2025 from $248,102 in fiscal 2024, attributed to cost-cutting measures due to lack of working capital.
• The company's cash balance as of June 30, 2025, was critically low at $12,088.
• A reverse stock split (1:60,000) became effective on January 29, 2025.
• Post-period, on August 18, 2025, the company completed a public offering, selling 1,000,000 shares of common stock for gross proceeds of $4,000,000, yielding net proceeds of $3,340,000 after expenses.
• The company plans to submit its Investigational Medicinal Product Dossier, study proposal, and Investigators Brochure in 2025, with CTA compilation and submission planned for the first half of calendar year 2026.
• A First-In-Human (FIH), Phase Ib study in advanced solid tumor patients is planned for the second half of calendar year 2026, with an estimated cost of approximately $6.5 million.
• PRP has received Orphan Drug Designation from the U.S. FDA for the treatment of pancreatic cancer in June 2017.
• The company has 85 granted, allowed, or accepted patents and 5 patent applications filed or under examination globally related to proenzymes against solid tumors.
• Material weaknesses in internal controls over financial reporting were identified, including lack of written documentation for policies and procedures and insufficient segregation of duties.
• The company's ability to continue as a going concern is in substantial doubt due to recurring losses, negative cash flows from operations, and dependence on future financing.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a massive net loss increase, critically low cash, and a going concern warning from auditors. While R&D progresses and a capital raise was completed post-period, the underlying financial instability and internal control weaknesses present significant challenges and high risk.

Positives

• PRP received Orphan Drug Designation from the U.S. FDA for pancreatic cancer in June 2017, offering developmental incentives like protocol assistance, potential research grants, waiver of application fees, and tax credits.
• The company has a robust intellectual property portfolio with 85 granted, allowed, or accepted patents and 5 patent applications filed or under examination in key global jurisdictions for proenzyme use against solid tumors.
• Successful preclinical studies on PRP have been conducted, showing anti-tumor effects and selective action against malignant cells without affecting non-tumor microenvironment.
• Clinical studies with a suppository formulation of proenzymes showed increased mean survival (9.0 months) compared to mean life expectation (5.6 months) in 41.3% of advanced metastatic cancer patients, with no severe side effects.
• The POP1 joint research and drug discovery program is progressing, having synthesized recombinant trypsinogen and chymotrypsinogen, aiming for animal-free, long shelf-life production.
• The company receives an up to 43.5% cash-back benefit from overseas R&D expenses in Australia, receiving $129,132 AUD in fiscal year 2024.
• A public offering completed on August 18, 2025, raised net proceeds of $3,340,000, providing much-needed capital.

Negatives

• Net loss significantly increased to $58,923,300 for fiscal year 2025 from $1,820,528 in fiscal year 2024.
• Administration expenses dramatically rose to $57,027,850 in fiscal year 2025, primarily due to $37,800,000 in stock-based compensation to officers and an employee, and $18,169,000 for stock-based consulting and legal services.
• The company's cash balance is extremely low at $12,088 as of June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and dependence on future financing.
• Material weaknesses in internal control over financial reporting were identified, including a lack of written documentation for internal control policies and procedures and insufficient segregation of duties.
• Many convertible notes and loans payable were past due and in default as of June 30, 2025, incurring higher default interest rates.
• The U.S. FDA denied orphan drug designation for ovarian cancer in November 2017 due to the prevalence exceeding the 200,000 case threshold.

Risks

• Ability to continue as a going concern absent new debt or equity financings.
• Ability to successfully remediate material weaknesses in internal controls.
• Ability to reach research and development milestones as planned and within proposed budgets.
• Ability to control costs, especially as R&D activities expand.
• Current reliance on substantial debt financing that the company is currently unable to repay in cash.
• Ability to obtain adequate new financing to fund planned Phase I, II, and III clinical trials and for working capital.
• Ability to successfully develop PRP, the lead product candidate, and successfully develop and market technologies.
• Ability to obtain and maintain patent protection for its intellectual property.
• Ability to recruit employees and directors with accounting and finance expertise.
• Dependence on third parties for services and on key executives.
• Impact of government regulations, including U.S. Food and Drug Administration regulations.
• Impact of any future litigation.
• Availability of capital and changes in economic, business, and competitive conditions.

Future Outlook

The company plans to submit its Investigational Medicinal Product Dossier, study proposal, and Investigators Brochure in 2025. CTA compilation and submission for PRP are anticipated in the first half of calendar year 2026, with approval expected in July 2026. A First-In-Human (FIH), Phase Ib study in advanced solid tumor patients is planned to commence in the second half of calendar year 2026, with an estimated cost of approximately $6.5 million, and completion hoped for within twelve months thereafter. Following Phase Ib, the company intends to conduct Phase IIa proof of concept studies for pancreatic and ovarian cancers and then seek a licensee for further development. Future R&D collaborations are under negotiation, and the company aims to identify and develop new, less toxic cancer treatments.

Management Comments

• Management believes the report fairly presents, in all material respects, the financial condition, results of operations, and cash flows of the registrant.
• Management acknowledges material weaknesses in internal control over financial reporting and plans to establish an audit committee, add experienced accounting personnel, and retain third-party consultants to review and improve internal controls.

Industry Context

The global metastatic cancer treatment market is projected to reach $111 billion by 2027, driven by an aging population and rising cancer incidence rates. The pancreatic cancer drug market is expected to grow to $6.93 billion by 2030, and the ovarian cancer drug market to $13.9 billion by 2029. Propanc Biopharma aims to capitalize on this demand with PRP, a 'first-in-class' proenzyme formulation, targeting aggressive tumor types with limited treatment options, such as pancreatic and ovarian cancers, which resulted in over 673,255 deaths combined globally in 2020.

Comparison to Industry Standards

• Propanc Biopharma positions PRP as a 'first-in-class' innovation, aiming for a molecular target and/or mechanism of action not found in any approved products globally, which offers the greatest degree of differentiation and potential market share capture.
• Current therapies for metastatic cancer, including chemotherapeutics, targeted therapies (e.g., multi-targeted kinase inhibitors), and monoclonal antibodies (e.g., Avastin), often have significant toxic effects, high costs, and limited survival benefits, with resistance development being a common issue.
• Immunotherapy, while generally having a better safety profile, is often limited to specific genetic sub-populations and a smaller number of eligible patients.
• Propanc's approach of inducing cell differentiation and targeting cancer stem cells, with evidence of no observable serious side effects in early human data, aims to provide a competitive advantage over existing treatments by offering a more effective therapy with a substantially reduced side effect profile.
• Major competitors in the pancreatic cancer therapy market include Eli Lilly and Company, Roche Holding AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Merck & Co., Inc.
• Major competitors in the global ovarian cancer treatment market include AbbVie Inc., AstraZeneca PLC (Acerta Pharma), Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co., Ltd., GSK plc (formerly, GlaxoSmithKline plc (Tesaro)), Gradalis, Inc., Incyte Corporation, MacroGenics, Inc., Oncotelic Therapeutics, Inc. (formerly, Mateon Therapeutics, Inc.), Merck & Co., Inc., Novartis AG, Kazia Therapeutics Limited (formerly, Novogen Limited), Vivesto AB (formerly, Oasmia Pharmaceutical AB), Pfizer Inc., Pharma Mar S.A., and Roche Holding AG.

Management Changes

Corporate Governance

Legal Proceedings

• The company incurred a penalty from the IRS totaling $30,000 plus accrued interest for non-timely filing of informational Form 5471 for fiscal years 2012 through 2014. This amount is included in accrued expenses and other payables.

Related Party Transactions

• Lease agreement for principal executive office with North Horizon Pty Ltd., a related party owned and directed by Mr. Nathanielsz (CEO, CFO, Director) and his wife. A new one-year lease was entered on May 4, 2025, for $3,300 AUD ($2,127 USD) per month plus taxes, with an option to renew for two additional years.
• Loans from an institutional investor affiliated with Josef Zelinger (Independent Director): various loans totaling $415,329 USD as of June 30, 2025, with some bearing interest rates of 12-18% per annum and several being past due and in default. A long-term loan of $230,000 AUD ($153,256 USD) was entered on July 5, 2023, with a 10% interest rate and warrants issued.
• Employment agreements with James Nathanielsz (CEO, CFO) and Sylvia Nathanielsz (non-executive, part-time employee and wife of James Nathanielsz), detailing salaries, bonuses, pension contributions, and vehicle expenses. Mr. Nathanielsz's annual base salary was increased to $600,000 AUD ($414,900 USD) effective July 1, 2022.
• Services agreement with Dr. Julian Kenyon (Chief Scientific Officer, Director) for an annual salary of $54,000 AUD ($41,580 USD) and equity awards.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity financings, as well as potential adverse impact on share price due to substantial losses, going concern issues, and internal control weaknesses.
• Employees and management received substantial stock-based compensation, which contributed to the large net loss but may incentivize retention and alignment with company performance.
• Creditors holding convertible notes and loans face repayment risk, as many debts are past due and in default, though some were repaid post-period with proceeds from the public offering.
• Patients with pancreatic, ovarian, and colorectal cancers could potentially benefit from PRP if clinical trials are successful, offering a novel, less toxic treatment option for metastatic disease.
• Research collaborators (University of Jan, University of Granada) benefit from ongoing joint research programs and potential royalties from future product sales.

Next Steps

• Submit Investigational Medicinal Product Dossier, study proposal, and Investigators Brochure in 2025.
• Commence study preparation process (CRO, analytical lab, trial site selection) in Q1 2026.
• Compile and submit Clinical Trial Application (CTA) for PRP in the first half of calendar year 2026.
• Begin preparation of logistics and trial site initiation visits in Q2 2026.
• Initiate a First-In-Human (FIH), Phase Ib study in advanced cancer patients with solid tumors in the second half of calendar year 2026.
• Complete the Phase Ib study within twelve months after initiation.
• Conduct Phase IIa proof of concept, multi-trial center studies for pancreatic and ovarian cancers after Phase Ib completion.
• Seek a licensee for further development beyond Phase IIa clinical trials.
• Continue research and development to build existing intellectual property portfolio and seek new patentable discoveries.
• Assess future opportunities to use management and scientific personnel expertise for prospective R&D projects.
• Establish an audit committee, add experienced accounting and financial personnel, and retain third-party consultants to review and recommend improvements for internal controls.

Key Dates

Recommendation

Propanc Biopharma presents an extremely high-risk investment profile. The company reported a staggering net loss of $58.9 million for fiscal year 2025, primarily driven by non-cash stock-based compensation, which, while not a cash outflow, significantly impacts reported earnings and shareholder equity. Cash on hand is critically low at $12,088, and the independent auditors have issued a 'going concern' qualification, indicating substantial doubt about the company's ability to continue operations. Numerous debt instruments are in default, and while a post-period capital raise provided some liquidity, it is unlikely to be sufficient for the long-term, multi-year, multi-million dollar clinical trial program. The identified material weaknesses in internal controls further compound the operational and financial risks. Despite promising preclinical R&D and Orphan Drug Designation for PRP, the company's financial instability, heavy reliance on dilutive financing, and significant operational challenges make it a 'strong sell' for seasoned investors, as the risk of substantial capital loss far outweighs the speculative potential for future drug development success.

Keywords

Biopharma, Cancer Treatment, Proenzyme Therapy, PRP, Oncology, Metastatic Cancer, Pancreatic Cancer, Ovarian Cancer, Drug Development, Clinical Trials, Orphan Drug Designation, SEC Filing, Biotechnology, Pharmaceuticals